Biological
Troculeucel clinical trials
Also written Natural killer cells and SNK01.
- studies test it
- 20
- open now
- 2
- in phase 3
- 0
- first study started
- 2005
Keep track of what changes. Save the troculeucel studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
Studies by the year they started
20 studies that test it; most in 2016 (7)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2008 | 1 |
| 2010 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2016 | 7 |
| 2017 | 1 |
| 2019 | 1 |
| 2021 | 3 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 16
- Phase 2
- 16
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 15
Fuda Cancer Hospital, Guangzhou (7) · NKGen Biotech, Inc. (5) · Masonic Cancer Center, University of Minnesota (4) · Hospital de Clinicas de Porto Alegre (2) · St. Jude Children's Research Hospital (1) · Monica Thakar (1)
Often tested with
Tested in the same studies.
Rituximab (2) · Aldesleukin (2) · Antineoplastic Agents (1) · Anti-EGFR/CD16A Bispecific Antibody AFM24 (1)
Studies
Open first, then newest update. How each study uses troculeucel is read from its arms, and is right about nine times in ten.
Testing it · 20
- Clinical Study of SNK01 in Participants With Moderate Alzheimer's DiseaseRecruitingPhase 1/2NKGen Biotech, Inc.NCT06189963Written as SNK01
- Open-Label Extension Protocol to SNK01-AD01 StudyRecruitingPhase 2NKGen Biotech, Inc.NCT07228078Written as SNK01
- Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid TumorsTerminatedPhase 2Monica ThakarNCT02100891Written as Donor NK Cell Infusion
- Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing CancersTerminatedPhase 1/2NKGen Biotech, Inc.NCT05099549Written as SNK01
- Safety of SNK01 in Subjects With Alzheimer's Disease (ASK-AD)TerminatedPhase 1NKGen Biotech, Inc.NCT04678453Written as SNK01
- Fase I Clinical Trial on NK Cells for COVID-19Status unknownPhase 1Hospital de Clinicas de Porto AlegreNCT04634370Written as Natural Killer Cells infusion
- Autologous Natural Killer Cells in Subjects With Plaque PsoriasisCompletedPhase 1NKGen Biotech, Inc.NCT03894579Written as Study Product: SNK01
- Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid LeukemiaStatus unknownPhase 1/2Hospital de Clinicas de Porto AlegreNCT02809092Written as NK Cells + Chemotherapy Starting
- High-activity Natural Killer Immunotherapy for Small Metastases of Tongue CancerCompletedPhase 1/2Fuda Cancer Hospital, GuangzhouNCT03008330Written as High-activity natural killer
- High-activity Natural Killer Immunotherapy for Small Metastases of Pancreatic CancerCompletedPhase 1/2Fuda Cancer Hospital, GuangzhouNCT03008304Written as High-activity natural killer
- High-activity Natural Killer Immunotherapy for Small Metastases of Nasopharyngeal CancerCompletedPhase 1/2Fuda Cancer Hospital, GuangzhouNCT03007836Written as High-activity natural killer
- High-activity Natural Killer Immunotherapy for Small Metastases of Colorectal CancerCompletedPhase 1/2Fuda Cancer Hospital, GuangzhouNCT03008499Written as High-activity natural killer
- High-activity Natural Killer Immunotherapy for Small Metastases of MelanomaCompletedPhase 1/2Fuda Cancer Hospital, GuangzhouNCT03007823Written as High-activity natural killer
- High-activity Natural Killer Immunotherapy for Small Metastases of Non-small Cell Lung CancerCompletedPhase 1/2Fuda Cancer Hospital, GuangzhouNCT03007875Written as high-activity natural killer
- Combination of Irreversible Electroporation and NK Immunotherapy for Recurrent Liver CancerCompletedPhase 1/2Fuda Cancer Hospital, GuangzhouNCT03008343Written as Natural killer
- Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory NeuroblastomaCompletedPhase 1St. Jude Children's Research HospitalNCT01576692Written as Natural killer cells
- Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid MalignanciesCompletedPhase 2Masonic Cancer Center, University of MinnesotaNCT01181258Written as Natural killer cells
- Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell TransplantCompletedPhase 1/2Masonic Cancer Center, University of MinnesotaNCT00303667Written as natural killer cells
- Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic LeukemiaTerminatedPhase 1/2Masonic Cancer Center, University of MinnesotaNCT00625729Written as allogeneic natural killer cells
- Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)TerminatedPhase 2Masonic Cancer Center, University of MinnesotaNCT01106950Written as Natural Killer Cells
Given in every arm · 7 — troculeucel is usual care beside what is tested
- NK Cells Infusions With Irinotecan, Temozolomide, and DinutuximabActive, not recruitingPhase 1/2Nationwide Children's HospitalNCT04211675Written as Natural Killer Cells
- Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in CancerSuspendedPhase 1David WaldNCT05400122Written as Natural Killer Cells
- Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional TherapyCompletedPhase 1NKGen Biotech, Inc.NCT03941262Written as SNK01
- Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803CompletedPhase 1Brenda Cooper, MDNCT02890758Written as Natural Killer (NK) Cells
- A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor TreatmentStatus unknownPhase 1/2NKMAX Co., Ltd.NCT04872634Written as SNK01 (Super Natural Killer Cells 01)
- Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR CancersWithdrawnPhase 1/2NKGen Biotech, Inc.NCT04464967Written as SNK01
- Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast CancerCompletedPhase 2Masonic Cancer Center, University of MinnesotaNCT01105650Written as Natural killer cells
Codes
What other systems call troculeucel · ClinicalTrials.gg INT016883
- UNII (FDA) IZR558KO53TROCULEUCELOne source FDA
- NCI Thesaurus C178330TroculeucelOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | IZR558KO53 | TROCULEUCEL | One source FDA |
| NCI Thesaurus | C178330 | Troculeucel | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.